The U.S. Food and Drug Administration (FDA) has approved axatilimab-csfr for the treatment of chronic graft-versus-host disease (cGVHD) in adults and certain pediatric patients who have undergone at least two prior lines of systemic therapy. This approval provides a new option for patients struggling with cGVHD, a complex and often debilitating condition that occurs following stem cell or bone marrow transplants when the donor’s immune cells attack the recipient’s tissues.